Repligen Corporation $RGEN Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,171 shares of the biotechnology company’s stock after selling 833 shares during the quarter. Mutual of America Capital Management LLC owned about 0.05% of Repligen worth $3,628,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in RGEN. Twin Tree Management LP purchased a new stake in Repligen in the 1st quarter valued at approximately $29,000. Signaturefd LLC boosted its holdings in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 274 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in Repligen in the 1st quarter valued at approximately $132,000. Finally, Hilltop National Bank purchased a new stake in Repligen in the 2nd quarter valued at approximately $147,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $165.20 on Friday. The business’s 50 day simple moving average is $131.75 and its 200-day simple moving average is $127.38. The firm has a market capitalization of $9.29 billion, a price-to-earnings ratio of -660.77, a price-to-earnings-growth ratio of 3.48 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. During the same period last year, the firm earned $0.40 EPS. Repligen’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. Jefferies Financial Group lowered their price objective on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, September 12th. Hsbc Global Res raised Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. HSBC began coverage on Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective on the stock. Finally, Wells Fargo & Company decreased their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.